Possible approaches to CYP2C9-guided prescription of sulfonylureas in Russia.

Anna Mosikian, Antonina Dolgorukova, Alsu Zalevskaya

Pharmacogenomics 2016 Dec

filter terms:

To evaluate a possible role of CYP2C9 genotyping for sulfonylureas (SUs) prescription in Russia. We have collected the current data on correlation between SUs pharmacodynamics and CYP2C9 polymorphisms. We have evaluated the frequency of CYP2C9 polymorphisms in Russia by reviewing the literature published from 2004 to 2015 on Russian CYP2C9. The genotype *1/*1, which confers risk for treatment failure, has a higher frequency (81.92%) in the non-Caucasians than that (64.92%) in the Caucasians. The Caucasians have a frequency (3.58%) of the poor metabolizers (*2/*2, *2/*3 and *3/*3) eight-times higher than that (0.44%) in the non-Caucasians, predisposing an increased risk of hypoglycemia. Considering the received data and the existed knowledge on CYP2C9 influence on SUs pharmacokinetics and pharmacodynamics, we propose a possible approach to CYP2C9-guided SUs prescription for Russians.

Citation

Anna Mosikian, Antonina Dolgorukova, Alsu Zalevskaya. Possible approaches to CYP2C9-guided prescription of sulfonylureas in Russia. Pharmacogenomics. 2016 Dec;17(18):2115-2126